Viltolarsen: First Approval-Reference-Cited by-同舟云学术

Viltolarsen: First Approval

Published:2020-06-09 Issue:10 Volume:80 Page:1027-1031
ISSN:0012-6667
Container-title:Drugs
language:en
Short-container-title:Drugs

Author:

Dhillon Sohita

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical)

Link

https://link.springer.com/content/pdf/10.1007/s40265-020-01339-3.pdf

Reference15 articles.

1. Verhaart IEC, Aartsma-Rus A. Therapeutic developments for Duchenne muscular dystrophy. Nat Rev Neurol. 2019;15(7):373–86.

2. Rodrigues M, Yokota T. An overview of recent advances and clinical applications of exon skipping and splice modulation for muscular dystrophy and various genetic diseases. Methods Mol Biol. 2018;1828:31–55.

3. US National Institutes of Health. Duchenne and Becker muscular dystrophy. 2020. https://ghr.nlm.nih.gov/condition/duchenne-and-becker-muscular-dystrophy#statistics. Accessed 21 May 2010.

4. Guiraud S, Davies KE. Pharmacological advances for treatment in Duchenne muscular dystrophy. Curr Opin Pharmacol. 2017;34:36–48.

5. Lee J, Yokota T. Antisense therapy in neurology. J Pers Med. 2013;3(3):144–76.

Cited by 143 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of classical Machine Learning-based algorithms to predict Triplex Forming Oligonucleotides;Computational and Structural Biotechnology Reports;2024-12

2. Current status and trends in small nucleic acid drug development: Leading the future;Acta Pharmaceutica Sinica B;2024-09

3. Corticosteroids for the treatment of Duchenne muscular dystrophy: a safety review;Expert Opinion on Drug Safety;2024-08-27

4. Comprehensive analysis of 2097 patients with dystrophinopathy based on a database from 2011 to 2021;Orphanet Journal of Rare Diseases;2024-08-24

5. Therapeutic Antisense Oligonucleotides in Oncology: From Bench to Bedside;Cancers;2024-08-23